Results 151 to 160 of about 21,874 (160)

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

Cancer Letters, 2017
Qi-Wei Jiang, , Zhe-Sheng Chen
exaly  

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

British Journal of Cancer, 2011
C M Nutting, D Lokanatha, S Temam
exaly  

Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib

Tumor Biology, 2015
Aidong Wen, Xiaofeng Lai, Wen Aidong
exaly  

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

Annals of Oncology, 2007
D J Kerr, D J Kerr, M R Middleton
exaly  

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

Annals of Oncology, 2011
P Fasching, J -U Blohmer, C Hanusch
exaly  

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Annals of Oncology, 2012
Stefania Gori, Giulio Metro, Giancarlo Bisagni   +2 more
exaly  

Capecitabine/lapatinib

Reactions Weekly, 2015
openaire   +2 more sources

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

British Journal of Clinical Pharmacology, 2009
exaly  

Capecitabine/lapatinib

Reactions Weekly, 2019
openaire   +1 more source

Lapatinib/osimertinib

Reactions Weekly, 2018
openaire   +1 more source